



National Institute of Public Health of Québec

- [Start](#)
- [Contact Us](#)

INSPQ

Specialized skills and information in public health

[Français](#)
[Español](#)

The Institute | skills | Publications

- 1. [Start](#)

Use of the vaccine against COVID-19 NVX-CoV2373 from Novavax (Nuvaxovid)

[Read the document](#)

- The NVX-CoV2373 (Nuvaxovid) is a vaccine against COVID-19 with recombinant proteins with adjuvant for use by people aged 18 years and over.
- Three of these randomized clinics have concluded an elevated efficacy of two doses of the Nuvaxovid vaccine. Nous ne disposons pas de données sur son efficacité à long terme ou contre le variant Omicron.
- Those cases of myocarditis were identified after the administration of the Nuvaxovid vaccine. The information available is still insufficient to determine whether or not there is a causal link between vaccination and these cases of myocarditis.
- Le Nuvaxovid is based on a class technology, which makes it possible to favor the acceptability of vaccination for people who have a veritable vaccination schedule based on the most recent technologies such as ARN messenger (mRNA).
- The experience accumulated with the mRNA vaccines is greater than that with the Nuvaxovid et leur efficacité appears slightly more elevated. For this reason, it is preferable to use mRNA vaccines for primary immunization and rappelling doses in the majority of situations.
- The CIQ recommends the use of the Nuvaxovid vaccine (in primary immunization or for a rappelling dose) for people under 18 years of age and over ayant une contre-indication à l'administration of an mRNA vaccine or who refuses a first dose or An additional dose of the best type of vaccinations.
- The CIQ recommends an interval of 8 weeks between the first 2 doses. For the rappel dose, an interval of 3 months or more after the last dose of the primary immunization is recommended.



Québec

- Author(s):**
- [Philippe DeWals](#)
 - [Yen Giang Bui](#)
 - [Nicholas Brousseau](#)

- Committee:**
- [Comité sur l'immunisation du Québec](#)

- Topics):**
- [Immunization](#)
 - [COVID-19](#)

- Post Type:**
- [interim guidance](#)

3 March 2022

Message date:

French ▾

- [The Institute](#)
- [Public Health Laboratory of Quebec](#)
- [Quebec Toxicology Center](#)
- [Contact Us](#)
- [Employment offers](#)
- [Site Map](#)

skills

- [Development of people and communities](#)
- [Infectious diseases](#)
- [Habits of life and prevention of chronic diseases](#)
- [Environmental health and toxicology](#)
- [indigenous health](#)
- [Occupational health](#)
- [Safety and Trauma Prevention](#)

Subscribe to our newsletter
Les Résonances
Or other publications

[subscribe here](#)

Follow us on :





[© Government of Québec, 2023](#)